Literature DB >> 33857746

Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy.

Jacob L Glass1, Andriy Derkach2, Patrick Hilden2, Amber King3, Susan K Seo4, Katya Ahr5, Ashwin Kishtagari6, Ross L Levine7, Martin S Tallman8, Dan Douer9.   

Abstract

Acute Promyelocytic Leukemia (APL) is a unique subtype of acute myeloid leukemia that is highly responsive to minimally myelosuppressive therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). We and others have observed a higher than expected incidence of herpes zoster reactivation in APL patients treated with ATO. Memorial Sloan Kettering Cancer Center (MSKCC) has been using ATO since 1997 in all relapsed APL patients, and more recently has included it in our front-line APL regimens. Here we present a retrospective analysis of the factors contributing to herpes zoster reactivation among APL patients.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute promyelocytic leukemia; Arsenic trioxide; Herpes zoster

Mesh：

Substances：

Year:  2021        PMID： 33857746      PMCID： PMC8187313          DOI： 10.1016/j.leukres.2021.106569

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.715


  19 in total

Review 1.  Clinical practice. Herpes zoster.

Authors:  John W Gnann; Richard J Whitley
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

2.  Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.

Authors:  Simon Mantha; Debra A Goldman; Sean M Devlin; Ju-Whei Lee; Diana Zannino; Marnie Collins; Dan Douer; Harry J Iland; Mark R Litzow; Eytan M Stein; Frederick R Appelbaum; Richard A Larson; Richard Stone; Bayard L Powell; Susan Geyer; Kristina Laumann; Jacob M Rowe; Harry Erba; Steven Coutre; Megan Othus; Jae H Park; Peter H Wiernik; Martin S Tallman
Journal:  Blood       Date:  2017-01-12       Impact factor: 22.113

3.  High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia.

Authors:  Masayuki Yamakura; Kenji Tsuda; Tomotaka Ugai; Hiroki Sugihara; Yuki Nisihida; Masami Takeuchi; Kosei Matsue
Journal:  Acta Haematol       Date:  2013-09-24       Impact factor: 2.195

4.  Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

Authors:  Uwe Platzbecker; Giuseppe Avvisati; Laura Cicconi; Christian Thiede; Francesca Paoloni; Marco Vignetti; Felicetto Ferrara; Mariadomenica Divona; Francesco Albano; Fabio Efficace; Paola Fazi; Marco Sborgia; Eros Di Bona; Massimo Breccia; Erika Borlenghi; Roberto Cairoli; Alessandro Rambaldi; Lorella Melillo; Giorgio La Nasa; Walter Fiedler; Peter Brossart; Bernd Hertenstein; Helmut R Salih; Mohammed Wattad; Michael Lübbert; Christian H Brandts; Mathias Hänel; Christoph Röllig; Norbert Schmitz; Hartmut Link; Chiara Frairia; Enrico Maria Pogliani; Claudio Fozza; Alfonso Maria D'Arco; Nicola Di Renzo; Agostino Cortelezzi; Francesco Fabbiano; Konstanze Döhner; Arnold Ganser; Hartmut Döhner; Sergio Amadori; Franco Mandelli; Gerhard Ehninger; Richard F Schlenk; Francesco Lo-Coco
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

5.  Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge.

Authors:  Wing-Yan Au; Yok-Lam Kwong
Journal:  J Am Acad Dermatol       Date:  2005-11       Impact factor: 11.527

6.  Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.

Authors:  Randy A Taplitz; Erin B Kennedy; Eric J Bow; Jennie Crews; Charise Gleason; Douglas K Hawley; Amelia A Langston; Loretta J Nastoupil; Michelle Rajotte; Kenneth V Rolston; Lynne Strasfeld; Christopher R Flowers
Journal:  J Clin Oncol       Date:  2018-09-04       Impact factor: 44.544

7.  Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.

Authors:  Bayard L Powell; Barry Moser; Wendy Stock; Robert E Gallagher; Cheryl L Willman; Richard M Stone; Jacob M Rowe; Steven Coutre; James H Feusner; John Gregory; Stephen Couban; Frederick R Appelbaum; Martin S Tallman; Richard A Larson
Journal:  Blood       Date:  2010-08-12       Impact factor: 22.113

Review 8.  The coagulopathy of acute promyelocytic leukaemia revisited.

Authors:  Eytan Stein; Brandon McMahon; Hau Kwaan; Jessica K Altman; Olga Frankfurt; Martin S Tallman
Journal:  Best Pract Res Clin Haematol       Date:  2009-03       Impact factor: 3.020

9.  Effect of arsenic on regulatory T cells.

Authors:  B Hernández-Castro; L M Doníz-Padilla; M Salgado-Bustamante; D Rocha; M D Ortiz-Pérez; M E Jiménez-Capdeville; D P Portales-Pérez; A Quintanar-Stephano; R González-Amaro
Journal:  J Clin Immunol       Date:  2009-02-27       Impact factor: 8.317

10.  Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia.

Authors:  Craig W Freyer; Chelsea E Peterson; Yun Man; Amanda Przespolewski; Jeffrey Baron; Selina M Luger
Journal:  Leuk Lymphoma       Date:  2020-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.